Eunice Wang, MD, chief of the Leukemia Service at the Roswell Park Comprehensive Cancer Center, discusses the outlook of acute myeloid leukemia (AML) treatment in the wake of new FDA-approved treatment options. Dr. Wang says it is exciting to be involved in the AML therapy field as she believes there are not...

Courtney DiNardo, MD, MSCE, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, presents promising results from the phase 3 VIALE-A trial. The trial uses a combination of venetoclax plus azacitidine for the treatment of...

Jessica Bauman, MD, assistant professor of hematology/oncology at Fox Chase Cancer Center, discusses recent advancements in non-small cell lung cancer (NSCLC) treatment using targeted RET-fusion mutation therapies. RET-fusion driver mutations are sometimes seen in NSCLC, particularly in patients with...